Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
OpGen, Inc. specializes in molecular diagnostics and genomic analysis, focusing on antibiotic resistance and infectious diseases. Its proprietary technology, including the Acuitas® platform, provides rapid and accurate testing solutions, positioning the company uniquely in the growing market for precision medicine.
OpGen generates revenue primarily through the sale of its molecular diagnostic tests, which leverage advanced genomic technologies to provide rapid results for antibiotic resistance. The high gross margin of 90% reflects the premium pricing of its proprietary tests, driven by their accuracy and speed compared to traditional methods.
Adoption rates of Acuitas® platform in hospitals and laboratories
Regulatory approvals for new diagnostic tests
Partnerships with healthcare providers and payers
Market expansion into international regions
Technological disruption from new diagnostic technologies
Regulatory changes affecting approval processes for diagnostic tests
Emergence of new competitors with innovative testing solutions
Price competition from established diagnostic companies
Limited liquidity due to low current ratio (0.09)
Potential cash flow challenges given negative operating cash flow
low - The demand for diagnostic testing is relatively inelastic, as healthcare spending tends to remain stable regardless of economic cycles.
Minimal impact on financing costs due to low debt levels (Debt/Equity of 0.06), but rising rates could indirectly affect healthcare budgets and spending.
minimal - The company has a very low debt level, reducing its sensitivity to credit market fluctuations.
growth - Investors seeking high growth potential in the healthcare diagnostics sector.
high - Given the company's recent stock performance and the inherent volatility in biotech stocks.
